Sandoz announced it will no longer pursue FDA approval for its proposed biosimilar rituximab; when it comes time to set the clocks back an hour for daylight saving time, hospitals opt for paper records during the night shift to compensate for challenges with electronic health records; new research on the effectiveness of over-the-counter (OTC) medicines finds little evidence that these products will relieve a child’s symptoms when sick.
After receiving a Complete Response Letter from the FDA for its proposed biosimilar rituximab, Sandoz has re-evaluated the environment and decided it will no longer pursue FDA approval for GP2013. The American Journal of Managed Care®’s The Center for Biosimilars® reported that Sandoz does not believe it can generate the data required before “patient and market place needs” in the United States are “satisfied.” Celltrion’s CT-P10 has already received a recommendation from an FDA advisory panel to be approved.
It happens every year, and yet when it comes time to set the clocks back an hour for daylight saving time, hospitals opt for paper records during the night shift to compensate for challenges with electronic health records. According to Kaiser Health News, information entered from 1 am to 2 am will likely be deleted when the clock sets back to 1 am and hospitals avoid software glitches by turning the software off and using paper charts for an hour. Care delivery also slows down during the hour.
New research on the effectiveness of over-the-counter (OTC) cough and cold medicines finds little evidence that these products will relieve a child’s symptoms when sick. According to The New York Times, a review in The BMJ highlighted that there are actually risks in using OTC medications in young children. The American Academy of Pediatrics recommends against using OTC cough and cold preparations in children under age 6. The FDA only recommends against use in children under age 2. Instead, pediatricians recommend offering plenty of fluids, ibuprofen or acetaminophen, and honey (for children older than 1 year).
Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer
March 28th 2024This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
CMS is highly likely to negotiate the price of the obesity medication semaglutide in the coming years; many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack; the US life expectancy increased for the first time in 2 years.
Read More